# Expected Output: Medication Interaction Review

This document shows the expected agent output when running the medication review prompt against the Alex Rivera reference patient pod. Your agent's output should cover the same findings, though wording may vary.

---

## 1. Medication Inventory

### Prescribed Medications (ClinicalGenerated)

| Medication | Dose | Frequency | Indication | Prescriber | Status |
|-----------|------|-----------|------------|------------|--------|
| Lisinopril | 20 mg | Once daily | Essential Hypertension | Dr. Sarah Chen | Active |
| Metformin | 1000 mg | Twice daily | Type 2 Diabetes | Dr. Sarah Chen | Active |
| Atorvastatin | 40 mg | Once daily | Hyperlipidemia | Dr. Sarah Chen | Active |
| Albuterol | 90 mcg/actuation | As needed | Mild Persistent Asthma | Dr. Sarah Chen | Active |
| Amlodipine | 5 mg | Once daily | Hypertension | Dr. Sarah Chen | **Discontinued** (2024-06-15) |

### Self-Reported Medications and Supplements (SelfReported)

| Item | Dose | Frequency | Reason | Status |
|------|------|-----------|--------|--------|
| Cetirizine (Zyrtec) | 10 mg | Once daily | Seasonal allergic rhinitis | Active |
| Potassium Chloride | 20 mEq | Once daily | Muscle cramps | Active |
| Fish Oil (Omega-3) | 1000 mg | Once daily | Cardiovascular health | Active |

## 2. Interaction Analysis

### CRITICAL: Lisinopril + Potassium Chloride Supplement

| Field | Value |
|-------|-------|
| **Severity** | HIGH |
| **Type** | Drug-supplement interaction |
| **Cross-provenance** | Yes -- ClinicalGenerated (Lisinopril) + SelfReported (KCl) |

**Mechanism:** Lisinopril is an ACE inhibitor that reduces aldosterone secretion, thereby decreasing renal potassium excretion. When combined with exogenous potassium supplementation (20 mEq/day), the risk of hyperkalemia (elevated serum potassium) is significantly increased.

**Clinical significance:** This interaction is classified as a major drug-supplement interaction. Hyperkalemia (K+ > 5.5 mEq/L) can cause life-threatening cardiac arrhythmias, including ventricular fibrillation and cardiac arrest.

**Provenance note:** The potassium supplement is `SelfReported` -- the prescribing physician (Dr. Sarah Chen) may not be aware of this supplement. The lisinopril prescription note explicitly states "Monitor potassium levels due to ACE inhibitor mechanism," indicating awareness of the K+-raising effect but no knowledge of the supplement.

### Low-risk: Fish Oil + Atorvastatin

| Field | Value |
|-------|-------|
| **Severity** | LOW |
| **Type** | Drug-supplement overlap |

**Mechanism:** Fish oil (omega-3 fatty acids) and atorvastatin both target lipid management. Fish oil primarily lowers triglycerides while atorvastatin targets LDL cholesterol. This combination is generally considered safe and potentially beneficial, particularly given Alex's elevated triglycerides (190 mg/dL).

**No action required.** This is a complementary rather than conflicting combination.

## 3. Lab Correlation

### Serum Potassium: 5.1 mEq/L -- CONFIRMS INTERACTION CONCERN

| Lab | Value | Reference Range | Interpretation | Date |
|-----|-------|----------------|----------------|------|
| **Serum Potassium** | **5.1 mEq/L** | 3.5 - 5.0 mEq/L | **Above normal** | 2026-01-15 |
| Serum Creatinine | 1.1 mg/dL | 0.7 - 1.3 mg/dL | Normal | 2026-01-15 |
| eGFR | 78 mL/min/1.73m2 | > 90 | Mildly decreased (CKD Stage 2) | 2026-01-15 |

**Analysis:** The serum potassium of 5.1 mEq/L is above the normal upper limit of 5.0 mEq/L. This borderline hyperkalemia is consistent with the predicted interaction between lisinopril (ACE inhibitor, reduces K+ excretion) and the self-reported potassium chloride supplement (adds exogenous K+).

**Compounding factors:**
- The mildly decreased eGFR (78 mL/min, CKD Stage 2) further reduces the kidney's capacity to excrete excess potassium
- The lab note itself reads: "Patient is on lisinopril (ACE inhibitor) which can elevate potassium. Verify patient is not taking potassium supplements. Recheck in 2 weeks."
- This lab note confirms the prescriber already suspected the risk but the supplement was never reported

### Additional Lab Context

| Lab | Value | Range | Interpretation |
|-----|-------|-------|----------------|
| HbA1c | 7.2% | 4.0 - 5.6% | Above target (<7.0%), suggest lifestyle modifications |
| Fasting Glucose | 142 mg/dL | 70 - 100 mg/dL | Elevated, consistent with diabetes |
| LDL Cholesterol | 112 mg/dL | < 100 mg/dL | Above target for diabetic patient |
| Triglycerides | 190 mg/dL | < 150 mg/dL | Borderline high |
| HDL Cholesterol | 48 mg/dL | > 40 mg/dL | Low-normal |

## 4. Recommendations

### Priority 1 (URGENT): Potassium Supplement Review

- **Action:** Discontinue potassium chloride supplement pending physician consultation
- **Reason:** Active hyperkalemia risk confirmed by lab result (K+ 5.1 mEq/L) in the context of ACE inhibitor therapy and mildly reduced renal function
- **Required:** Physician review. This agent does not have prescriptive authority.

### Priority 2: Serum Potassium Recheck

- **Action:** Repeat serum potassium lab within 1-2 weeks
- **Reason:** Lab note from 2026-01-15 recommended recheck in 2 weeks; verify whether levels have changed since last draw

### Priority 3: Communication Gap

- **Action:** Inform prescribing physician (Dr. Sarah Chen) about the self-reported potassium supplement
- **Reason:** The supplement has `SelfReported` provenance and appears in the wellness section, not the clinical medication list. The prescriber's lab note asks to "verify patient is not taking potassium supplements" -- confirming this information has not been communicated.

### Priority 4: Glycemic Control Review

- **Action:** Discuss HbA1c (7.2%, target <7.0%) and fasting glucose (142 mg/dL) at next visit
- **Reason:** Slightly above target; lifestyle modifications or medication adjustment may be warranted

## 5. Write-back: AIGenerated Observation

The agent writes the following observation to the Pod:

```turtle
@prefix cascade: <https://ns.cascadeprotocol.org/core/v1#> .
@prefix health: <https://ns.cascadeprotocol.org/health/v1#> .
@prefix clinical: <https://ns.cascadeprotocol.org/clinical/v1#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<urn:uuid:obs-ai-0001-medreview-20260220> a cascade:AIObservation ;
    cascade:observationType "MedicationInteractionFlag" ;
    cascade:severity "high" ;
    cascade:dataProvenance cascade:AIGenerated ;
    cascade:schemaVersion "1.3" ;
    cascade:summary "Potential hyperkalemia risk: concurrent use of lisinopril (ACE inhibitor, ClinicalGenerated) and self-reported potassium chloride 20 mEq supplement (SelfReported). Serum K+ is 5.1 mEq/L (above normal range 3.5-5.0). Risk compounded by mildly reduced eGFR (78 mL/min, CKD Stage 2)." ;
    cascade:evidence (
        <urn:uuid:med0-0001-aaaa-bbbb-ccccddddeeee>
        <urn:uuid:supp-0003-aaaa-bbbb-ccccddddeeee>
        <urn:uuid:1ab0-0009-aaaa-bbbb-ccccddddeeee>
        <urn:uuid:1ab0-0008-aaaa-bbbb-ccccddddeeee>
    ) ;
    cascade:recommendation "Discontinue potassium supplement pending physician review. Recheck serum potassium in 1-2 weeks. Inform Dr. Sarah Chen of self-reported supplement." ;
    cascade:requiresPhysicianReview true ;
    prov:wasGeneratedBy [
        a prov:Activity ;
        prov:label "AI Medication Interaction Review" ;
        prov:startedAtTime "2026-02-20T00:00:00Z"^^xsd:dateTime ;
        prov:wasAssociatedWith [
            a prov:SoftwareAgent ;
            prov:label "Cascade Medication Review Agent"
        ]
    ] .
```

---

**Disclaimer:** This analysis was generated by an AI agent and is not a substitute for professional medical judgment. All findings require review by a licensed healthcare provider before any clinical action is taken.